YD Bio Warrants (YDESW) Financials
Newest figures come from the 20-F for FY2025, filed May 26, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the YDESW SEC filings page.
YD Bio Limited Warrants (YDESW) reported $597K in revenue for fiscal year 2025, up 16.9% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (20-F and 6-K reports).
Financial Health Signals
We do not publish a peer-relative financial health score for YD Bio Limited Warrants, because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
YD Bio Limited Warrants passes 1 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
YD Bio Limited Warrants reported a net loss of $8.3M while operations used $6.6M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
YD Bio Limited Warrants generated $597K in revenue in fiscal year 2025. This represents an increase of 16.9% from the prior year.
YD Bio Limited Warrants's EBITDA was -$5.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. The change from the prior year is not meaningful, because that figure was zero or negative.
YD Bio Limited Warrants reported a net loss of $8.3M in fiscal year 2025. The change from the prior year is not meaningful, because that figure was zero or negative.
YD Bio Limited Warrants earned -$0.12 per diluted share (EPS) in fiscal year 2025. The change from the prior year is not meaningful, because that figure was zero or negative.
Cash & Balance Sheet
YD Bio Limited Warrants recorded an outflow of $8.0M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. The change from the prior year is not meaningful, because that figure was zero or negative.
YD Bio Limited Warrants held $6.0M in cash against $7K in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
YD Bio Limited Warrants's gross margin was 28.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 2.4 percentage points from the prior year.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not reported for fiscal year 2025.
Capital Allocation
YD Bio Limited Warrants invested $1.6M in research and development in fiscal year 2025. This represents an increase of 226.1% from the prior year.
YD Bio Limited Warrants invested $1.4M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 1822.2% from the prior year.
Not reported for fiscal year 2025.
YDESW Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F |
|---|---|---|---|
| Revenue | $597K+16.9% | $510K+45.8% | $350K |
| Cost of Revenue | $429K+21.0% | $355K+80.5% | $197K |
| Gross Profit | $167K+7.8% | $155K+1.2% | $153K |
| R&D Expenses | $1.6M+226.1% | $491K | N/A |
| SG&A Expenses | $3.8M+240.3% | $1.1M+601.6% | $161K |
| Operating Income | -$5.3Mn/m | -$1.5Mn/m | -$10K |
| EBITDA | -$5.3Mn/m | -$1.5Mn/m | -$7K |
| Interest Expense | N/A | $772-64.0% | $2K |
| Income Tax | -$2K-106.1% | $25K+513.2% | $4K |
| Net Income | -$8.3Mn/m | -$1.4M-10509.7% | $14K |
| EPS (Basic) | -$0.12n/m | -$0.02n/m | $0.00 |
| EPS (Diluted) | -$0.12n/m | -$0.02n/m | $0.00 |
| Diluted Shares (Avg) | 67M+3.1% | 65M0.0% | 65M |
YDESW Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F |
|---|---|---|---|
| Total Assets | $13.8M+100.7% | $6.9M | N/A |
| Current Assets | $9.7M+178.9% | $3.5M | N/A |
| Cash & Equivalents | $6.0M+91.8% | $3.1M+3496.3% | $87K |
| Short-Term Investments | $0n/m | $0n/m | $0 |
| Inventory | $1.9M+4934.3% | $37K | N/A |
| Accounts Receivable | $167K+93.4% | $87K | N/A |
| Long-Term Investments | $0n/m | $0n/m | $0 |
| Total Liabilities | $16.6M+5971.6% | $274K | N/A |
| Current Liabilities | $1.6M+524.8% | $263K | N/A |
| Non-Current Liabilities | $15.0M+137184.6% | $11K | N/A |
| Long-Term Debt | $7K | N/A | N/A |
| Total Equity | -$2.9M-143.3% | $6.6M+28560.7% | $23K |
| Retained Earnings | -$10.2Mn/m | -$1.9M | N/A |
Not reported in any period shown, so not listed: Goodwill.
YDESW Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F |
|---|---|---|---|
| Operating Cash Flow | -$6.6Mn/m | -$1.2Mn/m | -$56K |
| Depreciation & Amortization | $16K+59.3% | $10K+315.9% | $2K |
| Capital Expenditures | $1.4M+1822.2% | $75K+25732.4% | $290 |
| Free Cash Flow | -$8.0Mn/m | -$1.3Mn/m | -$56K |
| Investing Cash Flow | -$1.4Mn/m | -$2.9Mn/m | -$290 |
| Financing Cash Flow | $10.9M+52.8% | $7.1M+6146.1% | $114K |
Not reported in any period shown, so not listed: Stock-Based Compensation, Dividends Paid, Share Buybacks.
YDESW Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F |
|---|---|---|---|
| Gross Margin | 28.1%-2.4pp | 30.4%-13.4pp | 43.8% |
| Operating Margin | -883.3% | -286.5% | -2.8% |
| Net Margin | -1392.6% | -276.6% | 3.9% |
| Return on Equity | N/A | -21.4%-80.4pp | 59.0% |
| Return on Assets | -60.3%-39.8pp | -20.6% | N/A |
| Current Ratio | 5.88-7.3x | 13.18 | N/A |
| Liabilities-to-Equity | N/A | 0.04 | N/A |
| Asset Turnover | 0.040.0x | 0.07 | N/A |
| FCF Margin | -1346.6% | -254.3% | -16.0% |
Not reported in any period shown, so not listed: Debt-to-Equity.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Note: Shareholder equity is negative (-$2.9M), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| YD Bio Limited Warrants YDESW | FY2025 | $597K | -$8.3M | N/A | N/A | — |
| Megan Holdings Limited MGN | FY2025 | $20.7M | $217K | 1.1% | $59.1M | 43/100 |
| FBS Global Limited FBGL | FY2025 | $19.1M | -$1.5M | -7.9% | $2.8M | 43/100 |
| Mega Fortune Company Limited MGRT | FY2025 | $11.1M | $1.8M | 16.1% | $1.6B | 77/100 |
| Inventiva S.A. IVA | FY2025 | $5.3M | -$415.6M | N/A | $914.2M | 33/100 |
| NFT Limited MI | FY2025 | $726K | -$1.4M | N/A | $27.4M | — |
Where YD Bio Limited Warrants Ranks
Frequently Asked Questions
YD Bio Limited Warrants (YDESW) reported $597K in total revenue for fiscal year 2025. This represents a 16.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
YD Bio Limited Warrants (YDESW) revenue grew by 16.9% year-over-year, from $510K to $597K in fiscal year 2025.
No, YD Bio Limited Warrants (YDESW) reported a net loss of $8.3M in fiscal year 2025.
YD Bio Limited Warrants (YDESW) had EBITDA of -$5.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
As of fiscal year 2025, YD Bio Limited Warrants (YDESW) had $6.0M in cash and equivalents against $7K in long-term debt.
YD Bio Limited Warrants (YDESW) had a gross margin of 28.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
YD Bio Limited Warrants (YDESW) recorded an outflow of $8.0M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
YD Bio Limited Warrants (YDESW) recorded an outflow of $6.6M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
YD Bio Limited Warrants (YDESW) had $13.8M in total assets as of fiscal year 2025, including both current and long-term assets.
YD Bio Limited Warrants (YDESW) invested $1.4M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
YD Bio Limited Warrants (YDESW) invested $1.6M in research and development during fiscal year 2025.
YD Bio Limited Warrants (YDESW) had a current ratio of 5.88 as of fiscal year 2025, which is generally considered healthy.
YD Bio Limited Warrants (YDESW) had a return on assets of -60.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
YD Bio Limited Warrants (YDESW) has negative shareholder equity of -$2.9M as of fiscal year 2025, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
YD Bio Limited Warrants (YDESW) has a Piotroski F-Score of 1 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
YD Bio Limited Warrants (YDESW) reported a net loss of $8.3M while operations used $6.6M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.